{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"88.8","value":"25.0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"86.2","value":"11.1"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"88.3","value":"24.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"44"}],"units":"Participants"}],"description":"DOR for the subgroup of participants who achieved a CR or PR by independent central review, is the time from start of the first documentation of objective tumor response (CR or PR) to the first documentation of PD or to death due to any cause, whichever comes first based on BICR. CR is the disappearance of all evidence of disease and PR is the regression of measurable disease and no new sites. The analysis used the Kaplan-Meier method, with participants with response censored at their last assessment, and there was no progressive disease at the time of the last disease assessment.","dispersionType":"Full Range","groups":[{"description":"Participants with RRcHL who failed to achieve a response or progressed after auto-SCT and have relapsed after treatment with or failed to respond to BV post auto-SCT received pembrolizumab, 200 mg, intravenously (IV) every 3 weeks (Q3W) on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG000","title":"Cohort 1"},{"description":"Participants with RRcHL who were unable to achieve Complete Response (CR) or Partial Response (PR) to salvage chemotherapy and did not receive auto-SCT, but have relapsed after treatment with or failed to respond to BV received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle up to 35 cycles, for up to 24 months.","id":"OG001","title":"Cohort 2"},{"description":"Participants with RRcHL who failed to achieve a response to or progressed after auto-SCT and have not received BV post auto-SCT received pembrolizumab, 200 mg, IV Q3W on Day 1 of each 21-day cycle, up to 35 cycles for up to 24 months. These participants may or may not have received BV as part of primary treatment or salvage treatment.","id":"OG002","title":"Cohort 3"}],"paramType":"MEDIAN","populationDescription":"All allocated participants who received at least 1 dose of study treatment and had a CR or PR response.","reportingStatus":"POSTED","timeFrame":"Up to approximately 99 months","title":"Duration of Response (DOR) Based on BICR","type":"SECONDARY","unitOfMeasure":"Months"}